Effect of psoriasis activity on metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in plasma and lesional scales

被引:20
作者
Flisiak, I [1 ]
Porebski, P [1 ]
Chodynicka, B [1 ]
机构
[1] Med Univ Bialystok, Dept Dermatol & Venerol, PL-15540 Bialystok, Poland
关键词
psoriasis; metalloproteinase-1; tissue inhibitor of metalloproteinases-1; psoriasis area and severity index (PASI); skin diseases;
D O I
10.1080/0001555051001160
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The aim of this study was to evaluate the association between psoriasis severity and concentrations of matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in plasma and scales from psoriatic lesions, measured with an enzyme immuno assay in 24 patients and analysed with respect to psoriasis area and severity index (PASI). The mean plasma concentrations of both proteins in psoriatic patients significantly exceeded the control values. The proteins were also detectable in scales. There was a significant correlation between plasma MMP-1 concentration and the disease duration. The PASI values showed significant positive correlation with plasma TIMP-1 and significant negative correlation with MMP-1 content in scales. The highest plasma MMP-1 concentration was observed in patients with mild forms whereas the highest plasma TIMP-1 concentrations were demonstrated in severe forms of psoriasis. Our results confirm the role of these proteins in pathogenesis of psoriasis. In severe forms, a decrease in both MMP-1 and TIMP-1 was observed in scales, suggesting their insufficient tissue expression, which can be a crucial element of psoriasis aggravation.
引用
收藏
页码:17 / 21
页数:5
相关论文
共 26 条
[1]   Relationship between cell-associated matrix metalloproteinase 9 and psoriatic keratinocyte growth [J].
Buisson-Legendre, N ;
Emonard, H ;
Bernard, P ;
Hornebeck, W .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (02) :213-218
[2]   The 72-kDa and the 92-kDa gelatinases, but not their inhibitors TIMP-1 and TIMP-2, are expressed in early psoriatic lesions [J].
Feliciani, C ;
Vitullo, P ;
Dorazi, G ;
Palmirotta, R ;
Amerio, P ;
Pour, SM ;
Coscione, G ;
Amerio, PL ;
Modesti, A .
EXPERIMENTAL DERMATOLOGY, 1997, 6 (06) :321-327
[3]   Basement membrane alterations in psoriasis are accompanied by epidermal overexpression of MMP-2 and its inhibitor TIMP-2 [J].
Fleischmajer, R ;
Kuroda, K ;
Hazan, R ;
Gordon, RE ;
Lebwohl, MG ;
Sapadin, AN ;
Unda, F ;
Iehara, N ;
Yamada, Y .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (05) :771-777
[4]   Plasma transforming growth factor β1 as a biomarker of psoriasis activity and treatment efficacy [J].
Flisiak, I ;
Porebski, P ;
Flisiak, R ;
Chodynicka, B .
BIOMARKERS, 2003, 8 (05) :437-443
[5]   Association between psoriasis severity and transforming growth factor β1 and β2 in plasma and scales from psoriatic lesions [J].
Flisiak, I ;
Chodynicka, B ;
Porebski, P ;
Flisiak, R .
CYTOKINE, 2002, 19 (03) :121-125
[6]   SEVERE PSORIASIS - ORAL THERAPY WITH A NEW RETINOID [J].
FREDRIKSSON, T ;
PETTERSSON, U .
DERMATOLOGICA, 1978, 157 (04) :238-244
[7]  
Furue M, 1997, INT J CANCER, V71, P505, DOI 10.1002/(SICI)1097-0215(19970516)71:4<505::AID-IJC1>3.0.CO
[8]  
2-Y
[9]  
Giannelli G, 2004, CLIN EXP RHEUMATOL, V22, P335
[10]  
Gold LI, 2000, J PATHOL, V190, P579, DOI 10.1002/(SICI)1096-9896(200004)190:5<579::AID-PATH548>3.0.CO